logo-loader
viewIXICO PLC

IXICO signs contract to provide neuroimaging services for clinical trial for Huntington’s disease

IXICO PlC (AIM: IXI) Chief Commercial Officer, Lammert Albers joined Steve Darling from Proactive with news the company is to provide neuroimaging services that will support a phase Ib/II clinical trial for Huntington’s disease.

Albers telling Proactive "these services will enable clients to measure the impact of the trialled drugs with greater confidence and potentially unlock new insights into disease progression and drug development.”

Quick facts: IXICO PLC

Price: 89.8 GBX

AIM:IXI
Market: AIM
Market Cap: £42.33 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IXICO PLC named herein, including the promotion by the Company of IXICO PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Market report: UK approves Pfizer/BioNTech vaccine and lockdown ends

FTSE 100 consolidated after its recent surge even though there was more positive vaccine news and England’s lockdown ended. London’s blue-chip index was flat at 6,385 in early trading.   The UK has become the first country to approve the coronavirus vaccine developed by Pfizer Inc....

on 2/12/20

2 min read